Safety Shot Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Jarrett Boon

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	less than a year

Actualizaciones recientes de la dirección

Recent updates

Is Safety Shot (NASDAQ:SHOT) Using Debt In A Risky Way?

Mar 05

Jupiter Wellness to get US patent for minoxidil use in hair loss disorder

Sep 28

Jupiter Wellness inks exclusive licensing deal with Rejoy for new prescription products

Sep 20

Jupiter Wellness agrees with drug developer to refrain from exercising convertible note rights

Jul 26

Jupiter Wellness says developing a new women’s sexual health product

Jul 06

Jupiter Wellness: Advancing CBD-Based Medical Therapeutics And Wellness Products

Nov 30

Jupiter Wellness concludes enrollment in eczema study with JW-100

Dec 22

Vinco Ventures divests WOS to Jupiter Wellness

Dec 03

CEO

Jarrett Boon (56 yo)

less than a year

Permanencia

Mr. Jarrett Boon is Advisory Board Member of Mangoceuticals, Inc since January 06, 2023. He serves as Director at Safety Shot, Inc. (formerly known as Jupiter Wellness, Inc.) since October 10, 2023 and ser...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Brian John	Advisor	less than a year	US$477.96k	0% $ 0
Jarrett Boon	CEO & Director	less than a year	sin datos	sin datos
Jordan Schur	President & Director	less than a year	sin datos	6.77% $ 5.3m
Danielle Rosa-Diaz	Chief Financial Officer	less than a year	sin datos	0% $ 0
David Sandler	Chief Operating Officer	less than a year	sin datos	sin datos
Anthony Pedicelli	Director of Marketing	1.1yrs	sin datos	sin datos
Andy Goren	Chief Medical Officer & Member of Scientific Advisory Board	1.9yrs	sin datos	sin datos
Josh Wagner	Chief Revenue Officer	less than a year	sin datos	sin datos

0.2yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de SHOT no se considera experimentado ( 0.1 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jarrett Boon	CEO & Director	less than a year	sin datos	sin datos
Jordan Schur	President & Director	less than a year	sin datos	6.77% $ 5.3m
Andy Goren	Chief Medical Officer & Member of Scientific Advisory Board	2.8yrs	sin datos	sin datos
Hector Alila	Member of Scientific Advisory Board	1.7yrs	US$25.00k	0% $ 0
Christopher Melton	Independent Director	4.8yrs	US$25.00k	0% $ 0
Jack Brewer	Member of Advisory Board	less than a year	sin datos	sin datos
Richard Pascucci	Member of Advisory Board & Director	less than a year	sin datos	0% $ 0
Nancy Torres Kaufman	Independent Director	3.3yrs	US$25.00k	0% $ 0
David Long	Director & Member of Advisory Board	less than a year	sin datos	sin datos
John Gulyas	Independent Chairman	less than a year	sin datos	0.046% $ 36.0k

0.8yrs

Permanencia media

51yo

Promedio de edad

Junta con experiencia: La junta directiva de SHOT no se considera experimentada (0.8 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Safety Shot Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Safety Shot, Inc. Appoints David J. Long to the Board of Directors

Safety Shot, Inc Appoints Jordan Schur as President and Company Board Member

Safety Shot, Inc. Announces Chief Executive Officer Changes

Safety Shot, Inc. Appoints Danielle De Rosa as Chief Financial Officer, Effective March 1,2024

Less than half of directors are independent

Safety Shot Appoints Rich Pascucci to Its Board of Directors

Recent updates

Safety Shot, Inc. has filed a Follow-on Equity Offering in the amount of $4.999999 million.

New major risk - Revenue size

Full year 2023 earnings released: US$0.48 loss per share (vs US$0.70 loss in FY 2022)

Safety Shot, Inc. Appoints David J. Long to the Board of Directors

Safety Shot, Inc Appoints Jordan Schur as President and Company Board Member

Is Safety Shot (NASDAQ:SHOT) Using Debt In A Risky Way?

New minor risk - Market cap size

Safety Shot, Inc. Announces Chief Executive Officer Changes

Safety Shot, Inc. Appoints Danielle De Rosa as Chief Financial Officer, Effective March 1,2024

Less than half of directors are independent

Safety Shot Appoints Rich Pascucci to Its Board of Directors

Safety Shot, Inc. Announces West Coast Launch of Safety Shot

Safety Shot, Inc. announced delayed 10-Q filing

New major risk - Shareholder dilution

Safety Shot, Inc., Annual General Meeting, Dec 05, 2023

Safety Shot Inc. Announces Direct-To-Consumer Launch of Safety Shot

Safety Shot, Inc. Appoints Jarrett Boon to its Board of Directors

The Honorable Jack Brewer, M.Ed. Joins Safety Shot’s Advisory Board

Jupiter Wellness Appoints Jarrett Boon as COO

Jupiter Wellness Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Jupiter Wellness, Inc. Announces Chief Financial Officer Changes

Second quarter 2023 earnings released: US$0.013 loss per share (vs US$0.066 loss in 2Q 2022)

Jupiter Wellness, Inc. Appoints David Long to its Advisory Board

Jupiter Wellness, Inc Announces Board Appointments

Jupiter Wellness, Inc. Announces Executive Changes

New major risk - Share price stability

Jupiter Wellness, Inc. (NasdaqCM:JUPW) agreed to acquire Assets of GBB Drink Lab Inc.

First quarter 2023 earnings released: US$0.051 loss per share (vs US$0.13 loss in 1Q 2022)

Full year 2022 earnings released: US$0.69 loss per share (vs US$1.69 loss in FY 2021)

Jupiter Wellness, Inc. Appoints Hector Alila as Additional Director

Jupiter Wellness, Inc., Annual General Meeting, Dec 22, 2022

Jupiter Wellness Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jupiter Wellness Regains Compliance with Nasdaq Minimum Bid Price Requirement

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.24 loss in 3Q 2021)

Less than half of directors are independent

Jupiter Wellness, Inc. Re-Opens Enrollment in Clinical Trial Comparison of JW-100 and EUCRISA for the Treatment of Eczema

Director recently bought US$105k worth of stock

Jupiter Wellness, Inc. Initiates Clinical Trial for Potential New Treatment for Tinnitus

Jupiter Wellness to get US patent for minoxidil use in hair loss disorder

Jupiter Wellness inks exclusive licensing deal with Rejoy for new prescription products

Jupiter Wellness, Inc. Announces Board Changes, Effective September 15, 2022

Second quarter 2022 earnings released: US$0.066 loss per share (vs US$0.36 loss in 2Q 2021)

Jupiter Wellness agrees with drug developer to refrain from exercising convertible note rights

Jupiter Wellness says developing a new women’s sexual health product

Jupiter Wellness Receives Non-Compliance Notice from Nasdaq Related to Listing Rule 5635(c)

Jupiter Wellness Receives Non-Compliance Letter from Nasdaq

Jupiter Wellness, Inc. Appoints Prof. Andy Goren, MD as Chief Medical Officer

Jupiter Wellness, Inc. (NasdaqCM:JUPW) acquired Assets from Applied Biology, Inc. on June 21, 2022.

First quarter 2022 earnings released: US$0.13 loss per share (vs US$0.20 loss in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: US$1.69 loss per share (vs US$0.86 loss in FY 2020)

Jupiter Wellness, Inc. Announces Resignation of Ryan Allison as Chief Operating Officer

Less than half of directors are independent

Jupiter Wellness, Inc. Announces Executive Changes

Jupiter Wellness Communicates Nasdaq About Issue of Inadvertent Non-Compliance with Nasdaq Listing Rule 5635(C)

Jupiter Wellness, Inc. (NasdaqCM:JUPW) announces an Equity Buyback for $5 million worth of its shares.

Jupiter Wellness, Inc. (NasdaqCM:JUPW) signed a definitive agreement to acquire Next Frontier Brands.

Jupiter Wellness: Advancing CBD-Based Medical Therapeutics And Wellness Products

Third quarter 2021 earnings released: US$0.24 loss per share (vs US$0.088 loss in 3Q 2020)

CEO & Executive Director recently bought US$73k worth of stock

Second quarter 2021 earnings released: US$0.36 loss per share (vs US$0.062 loss in 2Q 2020)

Jupiter Wellness, Inc. Announces Inititation of Head-to-Head Trial Comparing JW-100 and Eucrisa® for the Treatment of Mild-to-Moderate Eczema

Jupiter Wellness, Inc. announced delayed annual 10-K filing

Jupiter Wellness, Inc. Announces Results of Clinical Study to Investigate the Safety and Efficacy of JW-100 its Proprietary Lotion Formulation for the Treatment of Atopic Dermatitis

New 90-day high: US$6.97

Jupiter Wellness Inc Appoints Ryan T. Allison as VP of Business Development

Jupiter Wellness, Inc. Appoints Nancy Torres Kaufman as A Director and Member of the Board's Audit Committee

Jupiter Wellness Completes Patient Enrollment in Clinical Study of Novel Cannabidiol Lotion JW-100 for the Treatment of Eczema

Jupiter Wellness concludes enrollment in eczema study with JW-100